Why Adaptimmune Therapeutics (ADAP) Stock Is Moving

Adaptimmune Therapeutics PLC – ADR ADAP shares are trading higher by 15.8% to $1.17 during Friday’s session after the company and Galapagos entered a clinical collaboration to license Adaptimmune’s uza-cel in head & neck cancer.

Uza-cel, which has shown an 80% response rate in a Phase 1 trial, is engineered to express the CD8α co-receptor, enhancing the immune response against tumors. 

The collaboration will utilize Galapagos’ decentralized cell manufacturing platform, which may improve the efficacy and durability of uza-cel and enable faster treatment delivery, with a vein-to-vein time of seven days.

See Also: Fed’s Preferred Inflation Gauge Matches Estimates; Personal Spending Slows More Than Predicted

How To Buy ADAP Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Adaptimmune Therapeutics’ case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, ADAP has a 52-week high of $2.05 and a 52-week low of $0.42.